P2, N=20, Recruiting, Icahn School of Medicine at Mount Sinai | Phase classification: P2a --> P2

P2, N=25, Not yet recruiting, Shanghai Zhongshan Hospital

P2, N=0, Withdrawn, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | N=168 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jan 2024 --> Apr 2024

P=N/A, N=120, Recruiting, Pfizer | Active, not recruiting --> Recruiting

P3, N=100, Completed, Pfizer | Active, not recruiting --> Completed

P2, N=30, Recruiting, Icahn School of Medicine at Mount Sinai

The probabilities of achieving target modified clinical remission and endoscopic improvement outcomes at both weeks 8 and 52 for ritlecitinib 100 mg once daily was 74.8%. Model-based assessment mitigated some of the risk associated with proceeding to pivotal phase 3 trials with dosing regimens of which there was limited clinical experience.

P1, N=12, Not yet recruiting, Pfizer

P=N/A, N=7807, Completed, Pfizer | N=4012 --> 7807

P2/3, N=275, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | Phase classification: P3 --> P2/3

P1, N=0, Withdrawn, Ornovi, Inc. | N=128 --> 0 | Trial completion date: Jun 2024 --> Feb 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2024 --> Feb 2024

P=N/A, N=24, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Feb 2022 --> Dec 2025 | Initiation date: Sep 2021 --> May 2024 | Trial primary completion date: Jan 2022 --> Jun 2025

P1, N=12, Completed, Pfizer | Recruiting --> Completed

P1/2, N=107, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active, not recruiting --> Completed

Except for one case of herpes simplex meningitis, the other cases, including ours, had improved disease activity without severe adverse events, and steroids and immunosuppressive medicines could be tapered. Tofacitinib could be considered an available therapy for refractory anti-MDA5 Ab + JDM.

Notably, the pharmacokinetic, physicochemical properties, and biological activities of the selected compounds (As compounds ZINC79189223 and ZINC66252348) were found to be consistent with their therapeutic effects in RA, owing to their non-toxic, cholinergic nature, absence of P-glycoprotein, high gastrointestinal absorption, and ability to penetrate the blood-brain barrier. Furthermore, ADMET properties were assessed, and molecular dynamics and MM/GBSA analysis revealed stability in these molecules.

P=N/A, N=60, Recruiting, Pfizer | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024

P1, N=32, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting

P=N/A, N=73, Completed, Pfizer | Active, not recruiting --> Completed

P=N/A, N=1, Completed, Pfizer | Trial primary completion date: Mar 2024 --> Oct 2023 | Recruiting --> Completed | Trial completion date: Mar 2024 --> Oct 2023

P1, N=26, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: May 2023 --> May 2025

P1, N=7, Completed, National Institute of Allergy and Infectious Diseases (NIAID) | Active, not recruiting --> Completed | N=10 --> 7

P4, N=92, Completed, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

P=N/A, N=130, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

In this Australian real-world dataset, tofacitinib was more frequently used in later lines and among a slightly higher proportion of female patients than IL-17Ai or TNFi. Overall, treatment persistence was similar for tofacitinib, IL-17Ai and TNFi, but tofacitinib exhibited longer persistence than TNFi in a matched population. Key Points • This is the first, large real-world study from Australia investigating the demographics, treatment patterns and comparative treatment persistence of patients with psoriatic arthritis (PsA) treated with tofacitinib and biologic disease-modifying drugs (bDMARDs). • The study suggests that tofacitinib is an effective intervention in PsA with at least comparable persistence to bDMARDs: tumour necrosis factor inhibitors (TNFi) and interleukin-17 A inhibitors (IL-17Ai).

VX-509 prevents the EMT process in CCSCs by inhibiting the transcription and protein expression of Nodal, and inhibits the dedifferentiated self-renewal of CCSCs.

P3, N=420, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=123, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P3, N=400, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial primary completion date: Dec 2023 --> Dec 2024

P1/2, N=160, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Recruiting --> Active, not recruiting | N=120 --> 160 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P1/2, N=107, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

P2, N=30, Recruiting, Massachusetts General Hospital | Trial completion date: Jan 2025 --> Aug 2025 | Trial primary completion date: Jan 2024 --> Aug 2025

P=N/A, N=850, Not yet recruiting, Pfizer

P1, N=12, Recruiting, Pfizer | Not yet recruiting --> Recruiting

P3, N=100, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting

P3, N=178, Recruiting, University Hospital, Bordeaux | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025

P2, N=91, Active, not recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P=N/A, N=103, Terminated, University of North Carolina, Chapel Hill | N=200 --> 103 | Trial completion date: Dec 2024 --> Jan 2024 | Enrolling by invitation --> Terminated; Futility; recruitment to slow to justify longer study duration

P4, N=15, Not yet recruiting, University of Alabama at Birmingham

P3, N=100, Recruiting, Pfizer | Active, not recruiting --> Recruiting

Furthermore, switching from tacrolimus to tofacitinib resulted in disease remission. Recognition of the inverse Gottron's sign may allow for the earlier diagnosis of anti-MDA5 Ab-positive dermatomyositis, and early addition of PE to triple therapy and administration of tofacitinib in refractory cases may be effective for anti-MDA5 Ab-positive CADM with RP-ILD under life-threatening conditions.